Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) 3-Year EBITDA Growth Rate : 0.00% (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings 3-Year EBITDA Growth Rate?

Cannabis Bioscience International Holdings's EBITDA per Share for the six months ended in Nov. 2023 was $0.00.

During the past 12 months, Cannabis Bioscience International Holdings's average EBITDA Per Share Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cannabis Bioscience International Holdings was -161.10% per year. The lowest was -161.10% per year. And the median was -161.10% per year.

Competitive Comparison of Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate falls into.

Cannabis Bioscience International Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cannabis Bioscience International Holdings (OTCPK:CBIH) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cannabis Bioscience International Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.